linjc16/ctgov huggingface dataset:
Diagnostic Ultrasound for Measuring Fat of the Body

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to provide information about human subcutaneous fat thickness at different anatomic sites on the body by measuring these thicknesses with a diagnostic ultrasound and also by correlating patient perceptions of body image with measured fat distribution. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

Official Title
-----------------
Diagnostic Ultrasound for Measuring Fat of the Body

Conditions
-----------------
Subcutaneous Fat

Intervention / Treatment
-----------------
* Diagnostic Test: LOGIQ P6 Diagnostic Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females 18-85 years old. Subjects are in good health as judged by the investigator. Subjects with Body Mass Index (BMI) between 18-29.99. Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator Exclusion Criteria: Evidence of another skin condition affecting the treatment area that would interfere with clinical assessments Pregnant or breast feeding Uncooperative patients or patients with neurological disorders who are incapable of following directions Subjects who are unable to understand the protocol or give informed consent (including non-English speaking patients)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental Group<br> | Diagnostic Test: LOGIQ P6 Diagnostic Ultrasound<br>* Ultrasound measurements of subcutaneous fat thickness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in Thickness of Subcutaneous Fat at Different Anatomic Sites on the Body | Will use diagnostic ultrasound to measure fat thickness | through study completion, 1 day | 
| Gender Differences on Patient Perceptions of Body Image With Measured Fat Distribution | Will use diagnostic ultrasound to measure fat thickness and a questionnaire to assess subject perceptions of their body using a 10-point Likert scale (1= very unsatisfied, 10= very satisfied) | through study completion, 1 day |
REtinaL Imaging & Ambulatory BLood PrEssure

Study Overview
=================
Brief Summary
-----------------
High blood pressure is a common condition which generally does not have any symptoms. Its estimated that around one third of people with high blood pressure do not know they have it. The back of the eye called the retina is one of the few places in the human body allowing easy observation of blood vessels. This study aims to see if simple non-invasive imaging of the blood vessels of the retina will highlight people with high blood pressure.

Detailed Description
-----------------
This will be a prospective, single centre study recruiting patients who are attending the ambulatory blood pressure clinic at the Western General Hospital. Suitable patients will be approached, and if they consent will have pictures of the back of each of their eyes taken. These pictures will then be reviewed, with certain measurements taken of the small blood vessels which can been seen at the back of the eye. These measurements will then be compared to the participants blood pressure readings to see if they might accurately correlate to blood pressure.

Official Title
-----------------
REtinaL Imaging & Ambulatory BLood PrEssure: Validating Ultra-widefield Retinal Imaging Derived Biomarkers Against Ambulatory Blood Pressure

Conditions
-----------------
Hypertension, Blood Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Attending ambulatory blood pressure clinic Able to undertake ambulatory BP measurement Able to undertake single clinic-based BP measurement Able to undergo UWF retinal imaging with a SLO Aged 18 to 90 Able to give informed consent Exclusion Criteria: People with known history of retinal surgery People under the age of 18 years. People that cannot: manoeuvre themselves to the SLO unaided, sit upright in a chair or wheelchair or position themselves comfortably for imaging. People with epilepsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Does retinal arteriovenous ratio correlate to systolic blood pressure | Retinal arteriovenous ratio (as measured by ultra-wide field imaging) will be correlated to mean daytime systolic blood pressure (as measured by 24-hour ambulatory blood pressure monitoring) | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Does retinal arteriovenous ratio correlate to clinic systolic blood pressure | Retinal arteriovenous ratio (as measured by ultra-wide field imaging) will be correlated to clinic systolic blood pressure. | 1 day |
Interaction Between Nalbuphine and Morphine in PCA

Study Overview
=================
Brief Summary
-----------------
Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist This study was designed to investigate the interaction between nalbuphine and morphine

Detailed Description
-----------------
Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist This study was designed to investigate the interaction between nalbuphine and morphine The analgesic effect and opioid-related side effects will be investigated

Official Title
-----------------
Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Nalbuphine and morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-65 y/o Female patients of ASA physical status I to III Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor Exclusion Criteria: Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants) Intraoperative fentanyl use > 3 μg/kg Patients with definite diagnosis of esophageal reflux syndrome Use of sedatives, antiemetics, or antipruritics within 24 hours before operation Surgery > 4 hours or laparoscopy surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nalbuphine and morphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| analgesic effect |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of opioid-related side effects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
analgeisa, postoperatve, side effects
Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face

Study Overview
=================
Brief Summary
-----------------
Clinical single-blind randomized comparison with the overall objective of evaluating the clinical efficacy of the products Nutracort lotion and Nutracort cream in the treatment of seborrheic dermatitis on the face. Will be held clinical and perceived efficacy assessment and instrumental measurements. Each product will be applied at half face for 7 consecutive days and all applications will be monitored in the research site. 60 volunteers will be recruited. Evaluations will be held at the following times: T0 - before the initial application of the product; T1 - 24 hours after starting treatment, T2 - 48 hours after starting treatment, T3 - 72 hours after initiation of treatment, T4 - 96 hours after the start treatment, T7 - 7 days after initiation of treatment.

Official Title
-----------------
Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face.

Conditions
-----------------
Seborrheic Dermatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects Subjects with seborrheic dermatitis on both sides of the face both sexes aged 18 to 60 years skin types I through IV. Exclusion Criteria: pregnancy / lactation skin condition in the area of application of the product diabetes immune insufficiency subjects that are using systemic corticoids subjects that are using immunosuppressors skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis history of reaction to the product category other diseases or medications that might interfere directly in the study or endanger the health of the subject

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence of COPD: First Epidemiological Data From a Large Region of Turkey

Study Overview
=================
Brief Summary
-----------------
The study was designed to obtain some baseline data on COPD in Malatya region of Turkey.

Detailed Description
-----------------
Sixty clusters from urban and rural regions were randomly selected. Ten and seven consecutive houses were included in the study from each urban and rural cluster respectively. A validated questionnaire on epidemiology of COPD was completed for each household over 18 by a pulmonary physician. Each subject performed the standard spirometric measurement and early bronchodilation testing.

Official Title
-----------------
Inonu University, The Department of Pulmonary Medicine

Conditions
-----------------
COPD Prevalance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All households over 18 were included in the study Exclusion Criteria: Age <18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, prevalence, smoke, biomass, occupational, Malatya, Turkey
Adrenaline Injections to Children Born at Elective CS

Study Overview
=================
Brief Summary
-----------------
Children born after elective C-section have a greater risk of respiratory problems and hypoglycemia - most likely due to a lower concentration of stress hormones compared to children born vaginally. Hypothesis: can we eliminate or reduce the risk of respiratory distress and hypoglycaemia by administrating adrenaline to the newborn.

Official Title
-----------------
Can the Risk of RD and Hypoglycemia in Children Born at Elective CS be Reduced by Injection of Adrenaline

Conditions
-----------------
Respiratory Distress, Hypoglycemia

Intervention / Treatment
-----------------
* Drug: Adrenaline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children born at elective section with gestational age more than 37 + 0 Exclusion Criteria: Children in whom a serious malformation was found during pregnancy assuming this malformation will lead to very early death or respiratory problems. Serious malformations (ex.anencephalia) will be excluded at birth Other malformations will be estimated by investigator whether it will lead to exclusion.

Ages Eligible for Study
-----------------
Maximum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Adrenaline|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| respiratory distress |  |  | 
| hypoglycemia |  |  |
Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
This is a 3-week study to evaluate FEV1 following treatment with drugs in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.

Official Title
-----------------
A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients With Seasonal Aeroallergen Sensitivity

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: montelukast sodium
* Drug: Comparator: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients, ages 6 to 14 years, with persistent asthma that is also active during allergy season Patients must demonstrate positive skin prick tests to seasonally relevant geographic aeroallergens Exclusion Criteria: Patient cannot have any other acute or chronic pulmonary disorder

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>montelukast | Drug: montelukast sodium<br>* montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.<br>* Other names: MK0476;|
| Placebo Comparator: 2<br>placebo | Drug: Comparator: Placebo<br>* Placebo. Up to 3 weeks of treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 | Percent change from baseline in FEV1, a measure of airway function, at Week 3 | Baseline and week 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Change From Baseline in Mean Daily as Needed β-agonist Use Over the 3-week Treatment Period | Percent change from baseline in average daily β-agonist use over the 3-week treatment period | Baseline and Week 3 |
Role of Pepsin Assay in Wheezy Infants

Study Overview
=================
Brief Summary
-----------------
Wheezy infants were tested for gastro-esophageal reflux disease (GERD) using combined multiple channel intraluminal impedance-pH (MII-pH), esophagogastroduodenoscope (EGD), lipid laden macrophage index and BAL pepsin. Wheezy infants with abnormal MII-pH or reflux esophagitis were given domperidone and omeprazole then re-evaluated for symptoms control and exacerbations recurrence.

Detailed Description
-----------------
Wheezy infants were tested for gastro-esophageal reflux disease using combined MII-pH, EGD, LLMI and BAL pepsin. Wheezy infants with abnormal MII-pH or reflux esophagitis were given domperidone and omeprazole for 12 weeks then re-evaluated for symptoms control and wheeze exacerbations recurrence.

Official Title
-----------------
Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants

Conditions
-----------------
Gastroesophageal Reflux Disease

Intervention / Treatment
-----------------
* Drug: Omeprazole and domperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants with physician documented 3 attacks of wheezing episodes over the last 6 months or persistent wheeze over the last one month Exclusion Criteria: Wheezy infants with atopy (allergic rhino-conjunctivitis or eczema), prematurity (less than 34 weeks), abnormal neurological examination, congenital heart diseases, airspace opacity on chest radiography, tracheal-bronchial malformations, immune deficiency and anatomical esophageal or gastric malformations

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: omeprazole and domperidone<br>wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day). | Drug: Omeprazole and domperidone<br>* wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)<br>* Other names: omipak , motilium;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants in Each Level of Wheeze Control | Number of Participants with controlled Wheezing Number of Participants with partially controlled Wheezing Number of Participants with uncontrolled wheezing | 3 months |
Supplemental Oxygen in Vascular Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to test the hypothesis that supplemental postoperative oxygen reduces the risk of surgical wound infection in patients following lower limb vascular surgery.

Official Title
-----------------
Supplemental Postoperative Oxygen and the Risk of Surgical Wound Infection in a Vascular Surgery Population: A Randomized Controlled Trial

Conditions
-----------------
Surgical Wound Infection, Vascular Surgery

Intervention / Treatment
-----------------
* Other: supplemental postoperative oxygen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lower limb vascular surgery Exclusion Criteria: COPD sPO2 less than 90%

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>recieves supplemental oxygen postoperatively | Other: supplemental postoperative oxygen<br> <br> |
| No Intervention: 2<br>treated as usual without supplemental oxygen | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| surgical wound infection |  | 30 days |
Reconfiguring the Patient Room to Increase Patient Stability

Study Overview
=================
Brief Summary
-----------------
Despite decades of research into patient falls, falls and the injuries incurred continue to be a serious threat to patient safety. Fall rates continue to be unacceptably high. The purpose of this project is to increase the safety of a hospital room for patient mobility, using innovative simulation strategies and patient-centric design.

Detailed Description
-----------------
Despite decades of research into patient falls, falls and the injuries incurred continue to be a serious threat to patient safety. Fall rates continue to be unacceptably high. The purpose of this project is to increase the safety of a hospital room for patient mobility, using innovative simulation strategies and patient-centric design. An innovative simulation environment will be built to enable rapid assessment of room layout and fixture positioning and patient stability. The results from multiple simulations will be used to fabricate a prototype room layout that will be tested by patients with Parkinson disease and reviewed and updated with input from other relevant stakeholders. A final room prototype will be built and tested. Results will be translated and shared with all stakeholders and disseminated for implementation.

Official Title
-----------------
Reconfiguring the Patient Room for a Fall Protection Strategy to Increase Patient Stability During Ambulation

Conditions
-----------------
Elderly, Frail, Accidental Falls, Hospitals

Intervention / Treatment
-----------------
* Other: Room configuration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Frail elderly, impaired gait Exclusion Criteria: Use of walking aid

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: Using virtual reality and ergonomic measures, we will sequentially adjust features of the hospital room to determine the most stable gate in frail elderly patients.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Participant stability with various room configurations<br>Single-arm. Ergonomically exploring patient stability moving around various configurations of a hospital room. | Other: Room configuration<br>* Adjust distance, handrails, degrees of turn for participant<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gait: increased stability | Increased balance | 24 months |